Grifols (GRFS) Competitors $7.98 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.92 -0.06 (-0.69%) As of 05/22/2026 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRFS vs. MRNA, VTRS, GMAB, ASND, and RGCShould you buy Grifols stock or one of its competitors? MarketBeat compares Grifols with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Grifols include Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry. GRFS vs. MRNAGRFS vs. VTRSGRFS vs. GMABGRFS vs. ASNDGRFS vs. RGCHow does Grifols compare to Moderna?Grifols (NASDAQ:GRFS) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends. Is GRFS or MRNA more profitable? Grifols has a net margin of 5.54% compared to Moderna's net margin of -143.55%. Grifols' return on equity of 6.21% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets Grifols5.54% 6.21% 2.39% Moderna -143.55%-26.64%-19.32% Do insiders & institutionals have more ownership in GRFS or MRNA? 75.3% of Moderna shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, GRFS or MRNA? Grifols has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$8.51B0.64$454.82M$0.1942.00Moderna$1.94B9.57-$2.82B-$8.15N/A Which has more volatility & risk, GRFS or MRNA? Grifols has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Do analysts prefer GRFS or MRNA? Grifols currently has a consensus target price of $10.00, indicating a potential upside of 25.31%. Moderna has a consensus target price of $35.73, indicating a potential downside of 23.78%. Given Grifols' higher possible upside, analysts plainly believe Grifols is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Moderna 5 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.84 Does the media refer more to GRFS or MRNA? In the previous week, Moderna had 15 more articles in the media than Grifols. MarketBeat recorded 17 mentions for Moderna and 2 mentions for Grifols. Grifols' average media sentiment score of 0.14 beat Moderna's score of -0.20 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryGrifols beats Moderna on 9 of the 16 factors compared between the two stocks.How does Grifols compare to Viatris?Viatris (NASDAQ:VTRS) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation. Do institutionals & insiders have more ownership in VTRS or GRFS? 79.9% of Viatris shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, VTRS or GRFS? Grifols has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.30B1.36-$3.51B-$0.26N/AGrifols$8.51B0.64$454.82M$0.1942.00 Do analysts recommend VTRS or GRFS? Viatris currently has a consensus target price of $16.43, indicating a potential downside of 1.33%. Grifols has a consensus target price of $10.00, indicating a potential upside of 25.31%. Given Grifols' higher possible upside, analysts clearly believe Grifols is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38Grifols 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Is VTRS or GRFS more profitable? Grifols has a net margin of 5.54% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Grifols' return on equity.Company Net Margins Return on Equity Return on Assets Viatris-2.04% 19.04% 7.62% Grifols 5.54%6.21%2.39% Which has more volatility & risk, VTRS or GRFS? Viatris has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Grifols has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Is VTRS or GRFS a better dividend stock? Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.9%. Grifols pays an annual dividend of $0.14 per share and has a dividend yield of 1.8%. Viatris pays out -184.6% of its earnings in the form of a dividend. Grifols pays out 73.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio. Does the media prefer VTRS or GRFS? In the previous week, Viatris had 1 more articles in the media than Grifols. MarketBeat recorded 3 mentions for Viatris and 2 mentions for Grifols. Viatris' average media sentiment score of 0.15 beat Grifols' score of 0.14 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryViatris beats Grifols on 13 of the 18 factors compared between the two stocks.How does Grifols compare to Genmab A/S?Genmab A/S (NASDAQ:GMAB) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings. Which has more volatility and risk, GMAB or GRFS? Genmab A/S has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Grifols has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Do insiders & institutionals believe in GMAB or GRFS? 7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer GMAB or GRFS? In the previous week, Grifols had 1 more articles in the media than Genmab A/S. MarketBeat recorded 2 mentions for Grifols and 1 mentions for Genmab A/S. Grifols' average media sentiment score of 0.14 beat Genmab A/S's score of 0.00 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation & earnings, GMAB or GRFS? Genmab A/S has higher earnings, but lower revenue than Grifols. Genmab A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.72B4.50$963M$1.3220.36Grifols$8.51B0.64$454.82M$0.1942.00 Do analysts rate GMAB or GRFS? Genmab A/S presently has a consensus target price of $39.07, indicating a potential upside of 45.41%. Grifols has a consensus target price of $10.00, indicating a potential upside of 25.31%. Given Genmab A/S's stronger consensus rating and higher possible upside, equities research analysts clearly believe Genmab A/S is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.83Grifols 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Is GMAB or GRFS more profitable? Genmab A/S has a net margin of 21.05% compared to Grifols' net margin of 5.54%. Genmab A/S's return on equity of 15.34% beat Grifols' return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S21.05% 15.34% 8.94% Grifols 5.54%6.21%2.39% SummaryGenmab A/S beats Grifols on 13 of the 17 factors compared between the two stocks.How does Grifols compare to Ascendis Pharma A/S?Grifols (NASDAQ:GRFS) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership. Which has stronger valuation and earnings, GRFS or ASND? Grifols has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$8.51B0.64$454.82M$0.1942.00Ascendis Pharma A/S$814.57M18.92-$258M$8.6728.49 Does the media prefer GRFS or ASND? In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Ascendis Pharma A/S and 2 mentions for Grifols. Ascendis Pharma A/S's average media sentiment score of 0.50 beat Grifols' score of 0.14 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, GRFS or ASND? Grifols has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Do analysts rate GRFS or ASND? Grifols presently has a consensus price target of $10.00, suggesting a potential upside of 25.31%. Ascendis Pharma A/S has a consensus price target of $295.39, suggesting a potential upside of 19.57%. Given Grifols' higher possible upside, research analysts plainly believe Grifols is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is GRFS or ASND more profitable? Ascendis Pharma A/S has a net margin of 57.87% compared to Grifols' net margin of 5.54%. Grifols' return on equity of 6.21% beat Ascendis Pharma A/S's return on equity.Company Net Margins Return on Equity Return on Assets Grifols5.54% 6.21% 2.39% Ascendis Pharma A/S 57.87%N/A -8.37% SummaryAscendis Pharma A/S beats Grifols on 8 of the 15 factors compared between the two stocks.How does Grifols compare to Regencell Bioscience?Grifols (NASDAQ:GRFS) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Is GRFS or RGC more profitable? Grifols has a net margin of 5.54% compared to Regencell Bioscience's net margin of 0.00%. Grifols' return on equity of 6.21% beat Regencell Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Grifols5.54% 6.21% 2.39% Regencell Bioscience N/A N/A N/A Do institutionals & insiders hold more shares of GRFS or RGC? 0.1% of Regencell Bioscience shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor GRFS or RGC? In the previous week, Regencell Bioscience had 15 more articles in the media than Grifols. MarketBeat recorded 17 mentions for Regencell Bioscience and 2 mentions for Grifols. Grifols' average media sentiment score of 0.14 beat Regencell Bioscience's score of 0.00 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 14 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend GRFS or RGC? Grifols currently has a consensus price target of $10.00, suggesting a potential upside of 25.31%. Given Grifols' stronger consensus rating and higher probable upside, analysts plainly believe Grifols is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has higher earnings & valuation, GRFS or RGC? Grifols has higher revenue and earnings than Regencell Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$8.51B0.64$454.82M$0.1942.00Regencell BioscienceN/AN/A-$3.58MN/AN/A Which has more risk and volatility, GRFS or RGC? Grifols has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. SummaryGrifols beats Regencell Bioscience on 8 of the 12 factors compared between the two stocks. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition ExportMetricGrifolsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.43B$3.03B$6.43B$12.32BDividend Yield1.78%1.97%2.76%5.28%P/E Ratio42.0017.7921.0125.66Price / Sales0.64500.74580.1698.40Price / Cash5.6357.7443.4956.67Price / Book0.595.8610.367.14Net Income$454.82M$74.99M$3.57B$335.98M7 Day Performance1.40%2.55%6.00%3.56%1 Month Performance-1.24%-3.05%3.51%2.54%1 Year Performance-1.60%34.38%34.12%35.05% Grifols Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols4.4322 of 5 stars$7.98flat$10.00+25.3%-1.6%$5.43B$8.51B42.0025,247MRNAModerna1.287 of 5 stars$48.11-1.9%$35.73-25.7%+78.5%$19.46B$1.94BN/A4,700Insider TradeVTRSViatris2.2229 of 5 stars$16.50+0.1%$15.71-4.8%+100.8%$19.19B$14.30BN/A30,000Ex-DividendGMABGenmab A/S3.8569 of 5 stars$26.37-0.6%$39.07+48.2%+29.1%$16.55B$3.72B19.983,029Gap DownASNDAscendis Pharma A/S3.5247 of 5 stars$237.64-1.2%$291.78+22.8%+52.5%$15.00B$814.57M27.411,189 Related Companies and Tools Related Companies MRNA Alternatives VTRS Alternatives GMAB Alternatives ASND Alternatives RGC Alternatives BBIO Alternatives SMMT Alternatives AXSM Alternatives RDY Alternatives ARWR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRFS) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
